Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir/rilpivirine - Janssen/ViiV Healthcare

Next Previous
Search
Drug Profile

Dolutegravir/rilpivirine - Janssen/ViiV Healthcare

Alternative Names: Dolutegravir sodium/rilpivirine hydrochloride; Juluca; Rilpivirine hydrochloride/dolutegravir sodium; Rilpivirine/dolutegravir

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Benzonitrile; Nitriles; Oxazines; Pyrimidines; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 30 May 2023 ViiV Healthcare completes the phase III SWORD-1 trial for HIV infections (Treatment-experienced) in USA, Argentina, Australia, Belgium, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, Taiwan, the UK (PO) (NCT02429791)
  • 25 May 2023 ViiV Healthcare completes the phase III SWORD-2 trial for HIV infections (Treatment-experienced) in the US, the UK, Argentina, Taiwan, Australia, Canada, France, Germany, Italy, Russia, and Spain (PO) (NCT reference) (NCT02422797)
  • 06 Jan 2023 ViiV Healthcare in a collaboration with Janssen Research & Development plans a phase I/II trial in HIV-1 infections (Treatment-experienced, In children) in February 2023 (NCT05674656)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top